Sandoz unveils generic oncology medicine Lenalidomide in Europe
Basel: Sandoz has recently announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines. The medicine will become available to patients in 19 countries across Europe."We are proud to make life-enhancing cancer treatments more accessible by launching...
Basel: Sandoz has recently announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines. The medicine will become available to patients in 19 countries across Europe.
"We are proud to make life-enhancing cancer treatments more accessible by launching our affordable and effective Sandoz Lenalidomide", said Rebecca Guntern, Head of Sandoz Europe.
She added: "Sandoz is committed to developing and providing generic oncology therapies, to increase patient access to affordable, high-quality medicines. Today, we offer a broad portfolio of more than 50 oncology products, ranging from biologics to chemotherapeutics, hormones and supportive care treatments, covering a wide range of cancer indications."
Read also: ANI Pharma acquires Sandoz NDAs to expand branded products portfolio
The cost of treating multiple myeloma patients is high and continues to rise. Affordability of and access to new multiple myeloma treatments pose a major challenge around the world. Cost savings from Lenalidomide Sandoz promise to expand access to treatment options for multiple myeloma patients. Similar to multiple myeloma patients, cost savings from Lenalidomide Sandoz will benefit previously treated follicular lymphoma patients, adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality, and relapsed or refractory mantle cell lymphoma patients.
Read also: Sandoz launches biosimilar Hyrimoz in Canada
Lenalidomide is an oral thalidomide analogue with immunomodulatory, antiangiogenic, and antineoplastic properties used for the treatment of various haemato-oncology conditions. It is available only through special distribution program because of its serious side effects, including possible birth defects or death of an unborn baby. Lenalidomide is available as hard capsules and need to be taken exactly as prescribed.
Read also: Sandoz launches intravenous medicine generic Ferumoxytol for iron deficiency anemia
Founded in 2003, Sandoz is a global pharmaceutical company headquartered in Basel, Switzerland.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd